Finanzen von Valion Bio Inc (VBIO)VBIOValion Bio Inc

Evaluating the bottom line, Valion Bio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -188.08%, provide a clear picture of how effectively VBIO converts its operational activities into shareholder value.

In the context of the broader market, VBIO competes directly with industry leaders such as BIAF and GCTK. With a market capitalization of $4.59M, it holds a significant position in the sector. When comparing efficiency, VBIO's gross margin of N/A stands against BIAF's 23.91% and GCTK's N/A. Such benchmarking helps identify whether Valion Bio Inc is trading at a premium or discount relative to its financial performance.

The company has shown significant financial distress, with total revenue of only $126,000 in Q3 2024 and a net income loss of $6.4 million in Q1 2026. The gross margin has fluctuated dramatically, peaking at 62.79% in Q2 2025 but dropping to negative values in subsequent quarters, indicating instability in its revenue generation.